Highly drug‐resistant HIV‐1 protease reveals decreased intra‐subunit interactions due to clusters of mutations
Open Access
- 23 January 2020
- journal article
- research article
- Published by Wiley in The FEBS Journal
- Vol. 287 (15) , 3235-3254
Abstract
Drug‐resistance is a serious problem for treatment of the HIV/AIDS pandemic. Potent clinical inhibitors of HIV‐1 protease show several orders of magnitude worse inhibition of highly drug‐resistant variants. Hence, the structure and enzyme activities were analyzed for HIV protease mutant HIV‐1 protease (EC 3.4.23.16) (PR) with 22 mutations (PRS5B) from a clinical isolate that was selected by machine learning to represent high‐level drug‐resistance. PRS5B has 22 mutations including only one (I84V) in the inhibitor binding site; however, clinical inhibitors had poor inhibition of PRS5B activity with kinetic inhibition value (Ki) values of 4–1000 nm or 18‐ to 8000‐fold worse than for wild‐type PR. High‐resolution crystal structures of PRS5B complexes with the best inhibitors, amprenavir (APV) and darunavir (DRV) (Ki ~ 4 nm), revealed only minor changes in protease‐inhibitor interactions. Instead, two distinct clusters of mutations in distal regions induce coordinated conformational changes that decrease favorable internal interactions across the entire protein subunit. The largest structural rearrangements are described and compared to other characterized resistant mutants. In the protease hinge region, the N83D mutation eliminates a hydrogen bond connecting the hinge and core of the protease and increases disorder compared to highly resistant mutants PR with 17 mutations and PR with 20 mutations with similar hinge mutations. In a distal β‐sheet, mutations G73T and A71V coordinate with accessory mutations to bring about shifts that propagate throughout the subunit. Molecular dynamics simulations of ligand‐free dimers show differences consistent with loss of interactions in mutant compared to wild‐type PR. Clusters of mutations exhibit both coordinated and antagonistic effects, suggesting PRS5B may represent an intermediate stage in the evolution of more highly resistant variants.Databases: Structural data are available in Protein Data Bank under the accession codes 6P9A and 6P9B for PRS5B/DRV and PRS5B/APV, respectively.Keywords
Funding Information
- National Institute of General Medical Sciences (AI150461)
This publication has 80 references indexed in Scilit:
- HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural RearrangementsBiochemistry, 2012
- Potent Antiviral HIV-1 Protease Inhibitor GRL-02031 Adapts to the Structures of Drug Resistant Mutants with Its P1′-Pyrrolidinone RingJournal of Medicinal Chemistry, 2012
- Accessory Mutations Maintain Stability in Drug-Resistant HIV-1 ProteaseJournal of Molecular Biology, 2011
- Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitorsProceedings of the National Academy of Sciences, 2011
- The L76V Drug Resistance Mutation Decreases the Dimer Stability and Rate of Autoprocessing of HIV-1 Protease by Reducing Internal Hydrophobic ContactsBiochemistry, 2011
- Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV‐1 protease: Relevance to drug resistanceProtein Science, 2010
- Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and DarunavirJournal of Molecular Biology, 2008
- Hydrophobic Sliding: A Possible Mechanism for Drug Resistance in Human Immunodeficiency Virus Type 1 ProteaseStructure, 2007
- Genotypic predictors of human immunodeficiency virus type 1 drug resistanceProceedings of the National Academy of Sciences, 2006
- [20] Processing of X-ray diffraction data collected in oscillation mode1997